Teva Pharmaceuticals

Teva Pharmaceuticals, an organisation in the Pharmaceutical Preparation Manufacturing industry headquartered in Israel, has reported a total of approximately 3.53 billion kg CO2e for the year 2025. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions.

For Scope 1, Teva Pharmaceuticals recorded approximately 229.33 million kg CO2e in 2025. Scope 2 emissions, based on market-based reporting, were approximately 161.99 million kg CO2e for the same year. The company's Scope 3 emissions for 2025 totalled approximately 3.14 billion kg CO2e. Key contributors to Scope 3 emissions include purchased goods and services (approximately 2.17 billion kg CO2e), end-of-life treatment of sold products (approximately 427.84 million kg CO2e), and use of sold products (approximately 715.33 million kg CO2e).

Teva Pharmaceuticals has established several climate commitments. The company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 and by 46% by 2030, using 2019 as a baseline year. Furthermore, Teva has stated its intention to achieve net-zero emissions across its operations and value chain by 2045. In line with this, Teva has also committed to a 25% reduction in absolute Scope 3 GHG emissions by 2030, compared to a 2020 baseline. These targets are consistent with keeping global warming to 1.5°C.